GMED · Globus Medical Inc · Insider Trading

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

These options were granted on January 27, 2022 and are fully vested.

These options were granted on January 26, 2024 and are fully vested.

These options were granted on January 22, 2020 and are fully vested.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.92 to $87.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price range of $80.59 - $80.92, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (1) of this Form 4.

These options were granted on January 30, 2017 and are fully vested.

These options were granted on January 30, 2017 and are fully vested.

This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated November 12, 2025 executed by the reporting person.

These options were granted on January 22, 2019 and are fully vested.

These options were granted on February 2, 2018 and are fully vested.

This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated November 12, 2025 executed by the reporting person.

These options were granted on January 21, 2026, and will vest on January 1, 2027.

These options were granted on January 21, 2026, and vest over a four-year period with 1/4 of the options vesting on January 1, 2027, then 1/48 of the options vesting each month thereafter.

These options were granted on January 21, 2026, and will vest on January 1, 2027.

These options were granted on January 21, 2026, and will vest on January 1, 2027.

These options were granted on January 21, 2026, and vest over a four-year period with 1/4 of the options vesting on January 1, 2027, and then 1/48 of the options vesting each month thereafter.

These options were granted on January 21, 2026, and vest over a four-year period with 1/4 of the options vesting on January 1, 2027, and then 1/48 of the options vesting each month thereafter.

These options were granted on January 21, 2026, and will vest on January 1, 2027.

These options were granted on January 21, 2026, and will vest on January 1, 2027.

These options were granted on January 21, 2026, and will vest on January 1, 2027.

These options were granted on January 21, 2026, and will vest on January 1, 2027.

These options were granted on January 21, 2026, and will vest on January 1, 2027.

These options were granted on January 21, 2026, and vest over a four-year period with 1/4 of the options vesting on January 1, 2027, and then 1/48 of the options vesting each month thereafter.

These options were granted on January 21, 2026, and will vest on January 1, 2027.

This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated September 12, 2025 executed by the reporting person.

This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated August 25, 2025 executed by the reporting person.

These options were granted on March 14, 2024, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2025, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

This sale was effectuated pursuant to a Rule 10b5-1 Trading Plan dated September 12, 2025 executed by the reporting person.

These options were granted on January 25, 2016 and are fully vested.

On December 3, 2025, the reporting person filed a Form 4 which inadvertently reported in Table II that 5,000 options were exercised prior to the sale of the underlying 4,896 shares of the issuer's Class A Common Stock that was reported in Table I. As correctly reported in this amendment, the reporting person exercised 4,896 options prior to the sale of the underlying 4,896 shares of the issuer's Class A Common Stock.

These options were granted on January 27, 2022, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2023, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated December 4, 2024 executed by the reporting person.

These options were granted on February 2, 2017 and are fully vested.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at a price range of $86.00 - $86.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (1) of this Form 4.

These options were granted on January 25, 2016 and are fully vested.

These options were granted on May 1, 2019 and are fully vested.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.11 to $84.65, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.